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A  Study on  Bacteriological profile of Plueral effusion and study on Adenosine 
deaminase level in  tuberculous and Non tuberculous pleural effusion. 
Abstract 
Background.  
  
The incidence of pleural infection continues to rise  worldwide. Identifying the 
causative organism  is important to guide antimicrobial therapy. The bacteriology 
of pleural infection is complex and has changed over time Diagnosis of Tuberculous 
pleural effusion   by culure , biopsy  is  time consuming.  Screening test to identify TB 
pleural effusion needed. 
 
 Materials and Methods:. 150 patients with pleural effusion were included n the 
study.AFB staining, Gram staining and culture  methods  for aerobic bacteria were 
done.Adenosine deaminase estimation was done. Culture for Mycobacterium done n 
Middlebrook 7H9 broth. Rapid test  MPT 64 Ag test was done from  Culture positive 
broth. 
 
Results. A total of 44 microorganisms were identified from the pleural fluid of 150 
patients. Gram-negative organisms was most commonly isolated  (68.18%), Among 
GNB Klebsiella pneumoniae was common ( 43.33%). Staphylococcus aureus  was the 
only Gram positive isolate (31.81%. ESBL production occurred mostly in Escherichia 
coli and Klebsiella oxytoca (100%). In Klebsiella pneumoniae  ESBL production was 
30.76%. 
Adenosine de aminase levels were elevated in 28 samples (18.66%).Among ADA 
elevated samples (Total 28) 14 patients had the diagnosis of   TB  , 14 had   
Malignancy . Total number of Malignant pleural effusion was 27  among 150.ie In TB 
pleural effusion ADA levels were elevated in 100%..In malignancy ADA levels 
elevated in 51.85%.Mean ADA value in TB pleural effusion was 80.45 U/l. Mean 
ADA value in Malignancy was 28.085%. 
 
 Conclusion: 
           Physicians need to know the local prevalence of microorganism  and their 
antibiotic susceptibility pattern in  Pleural effusion. ADA   estimation can  be   done 
for diagnosis for Tuberculous pleural effusion in India where TB is prevalent  and 
highly morbid,as an initial screening test. 
Keywords: Pleural effusion, Bacteriological profile, Adenosine deaminase, 
Tuberculous pleural effusion. 
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                                               INTRODUCTION 
                      “Pleural effusion   is   an abnormal and excess accumulation of fluid 
in pleural space”.(2, 6) This is not a disease per se but   often associated with   or 
manifested as a   symptom of an underlying diseases.  The most common   clinical 
conditions that    causes effusions are cardiac failure, pneumonia, and malignant 
neoplasm.(2, 6, 15) Diagnosis of a pleural effusion begins with obtaining the patient’s 
clinical history   and doing a physical examination   and is followed by chest 
radiography and analysis of pleural fluid in appropriate   instances.(2, 15)  If 
necessary, the process continues with further investigative studies, such as 
computed tomography (CT) of the thorax, pleural biopsy, thoracoscopy, and 
occasionally bronchoscopy.(2, 15)   
                       Pneumonia is often     associated with   exudative effusions and it also 
remains as the most common cause of pleural effusion in patients of younger age 
group.(13) Simple parapneumonic effusion progress to complicated para pneumonic 
effusion and empyema.(13)   Pus in the pleural space is called as empyema.(6, 13) Para 
pneumonic effusion and   empyema are a common clinical problem without a good 
variety of treatment options, occasionally having poor outcomes. Empyema   is 
mostly a complication of pneumonia   but sometimes may due to infections at other 
sites.(14) The causative microbes  of pleural space infections has changed since the 
introduction of antibiotics,  and  is modified by either specific patient factors such 
as  surgical procedures, trauma or underlying conditions, or by  methodological 
factors, namely the proper specimen collection, transport and culture.(13) For these 
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reasons, several   studies have found discordant  results in the spectrum of 
pathogens causing pleural infections.  
                      Malignancy   is the second most common cause of   Pleural 
effusion.(2,13) Usually causes bilateral pleural effusion.  It   is mostly common in 
elderly individuals. It causes exudative pleural effusion. Lung, breast, lymphoma 
are the primary site mostly resulting in the metastases to the pleura.(2, 3, 4, 13) 
                     Mesothelioma is due to previous asbestos exposure. It is   a malignant 
tumour of the pleura and peritoneum.(2, 3, 4, 13) There is a lag   period of many years 
nearly 15–40 years between exposure and disease  development.(13) 
 
 Tuberculous pleural effusion:  
                     Tuberculosis of pleura is the second most involvement site of extra 
pulmonary tuberculosis.  First   common site of extra pulmonary  TB  is   
Lymphnode. 
                      Delayed hypersensitivity   reaction to mycobacteria in the pleural 
space leads to Pleural effusion due.  It follows rupture of a subpleural caseous 
focus. It   occurs commonly   in   endemic areas. In areas with a high prevalence of   
tuberculosis, TB pleural effusion occurs as primary infection in younger ones, as 
disease reactivation in older patients.  
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Difficulties in definitive diagnosis of   Tuberculous pleurisy: 
                     
                  Tuberculin skin tests is less sensitive and has limited use in the 
investigation of TB pleurisy, mainly in HIV patients. Pleural fluid is usually a 
serous exudate, and   glucose concentration   and   pH values are decreased   in       
minority of patients.(25)  Pleural fluid lymphocytosis is a typical finding, although a 
neutrophilia may be seen  in the early stage. In order to achieve a definitive 
diagnosis of TB pleurisy, M.tuberculosis must be isolated from the pleural fluid or 
tissue culture.  The suggestive feature of TB pleurisy is    the presence of 
granulomas in pleural tissue from biopsy.(25)  
                      
                     Studies   have reported variable results for the diagnosis of TB 
effusions; reported sensitivities range from   10% to 47% for      pleural fluid 
culture, 39% to 84% for pleural biopsy histology   and 56% to 82% for pleural 
biopsy culture.  Pleural biopsy   is an invasive procedure. Combined culture and 
histology of pleural biopsy specimens has a greater diagnostic yield than histology 
alone.(25)  
 
                      The use of markers such as adenosine deaminase (ADA) in pleural 
fluid may be helpful in the early diagnosis of TB pleurisy. Pleural fluid ADA levels 
are   high not only   in pleural tuberculosis. An elevated value may be also   seen in 
other    infection and malignancy. The value of ADA depends on both the local 
prevalence of TB and the possibility of an alternative diagnosis. In areas where 
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tuberculosis is prevalent, an elevated ADA value is   highly sensitive and specific, 
mainly in young patients, after empyema has been excluded. In this condition 
treatment   without pleural biopsy may be considered.(8, 17, 18, 23)  
 
                      This   study is focused on   bacteriological profile and  their drug 
susceptibility pattern  which helps physicians to know the prevalence of bacterial 
cause in the  area  and  their antibiotic susceptibility pattern  and  the  diagnostic 
value of ADA level estimation   in Tuberculous  pleural effusion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
AIMS AND OBJECTIVES 
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                                           AIMS AND OBJECTIVES 
• To study the bacteriological profile of Pleural effusion and their antibiotic   
sensitivity pattern. 
• To study the Mycobacterial etiology of Pleural effusion. 
• To estimate the ADA values in Tuberculous Pleural effusion and non 
tuberculous pleural effusion. 
• To correlate elevated ADA levels with TB pleural effusion with liquid 
culture method and AFB smear positivity. 
• To find the sensitivity   and efficiency   of   ADA estimation in diagnosis of 
TB pleural effusion.  
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                                              REVIEW OF LITERATURE  
  
PLEURAL EFFUSION: 
                   “Pleural effusion is defined as an abnormal fluid accumulation in the 
Pleural cavity.”(2) Excessive fluid results due to variations in the equilibrium that 
exists across the pleural space. The cause and amount of fluid   are related to   the 
effects of accumulation of fluid in the Pleural space.  
ANATOMY: (1) 
                   The pleural space is bounded by Parietal and Visceral pleura.   It is a 
serous layer of mesodermal origin. It consists of mesothelial cells as a single layer, 
without a basement membrane. Pleura is separated   from the adipose tissue of the 
chest wall and from alveoli by a layer of connective tissue.(1) 
                             Parietal pleura cover the inner surface of the thoracic cavity, including 
the mediastinum, diaphragm and ribs. 
                  The visceral pleura covers the lung is indented into the fissures. It is 
continuous at the hilum with parietal pleura that lines the   inner side of thorax.(1) 
                  The Parietal and Visceral pleura are normally separated by a minimal 
quantity of fluid. The fluid is derived from   Parietal pleural capillaries.  The fluid is 
reabsorbed by mainly in costal and mediastinal pleural lymphatics.  If  the drainage 
pathway is blocked by   tumour cell, it lead to Pleural effusion.(1)  If the drainage 
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capacity of Pleural lymphatics  has overcomed by transudation or exudation of fluid 
between the two layers, the Pleural space become evident.(1) 
                 The arterial supply of visceral pleura is mainly derived by branches of the 
bronchial artery that divide into a network of dilated capillaries. The costal part of 
the parietal pleura is derives blood supply from intercostal arteries. 
Pericardiophrenic branch of the internal mammary artery supplies diaphragmatic 
and mediastinal part of Pleura.(1) 
                  The lymphatic drainage of the visceral Pleura is in the interlobular 
vessels and to hilar nodes. The lymphatics of the pareital pleura drain into internal 
mammary and intercostals nodes. 
                   The visceral pleura have autonomic nerve supply only.  So it is 
insensitive pain. Sensory nerves are present in the parietal pleura from spinal nerves 
over the ribs and from the phrenic nerve over the central part of the diaphragm.  
Pleural pain therefore denotes stimulation of the parietal receptors. Presence of 
phrenic supply to the central diaphragmatic pleura explains the referral pain from 
diaphragmatic pleurisy to the shoulder tip. Other pleural pain referred to the chest 
wall.(1) 
PHYSIOLOGY OF PLEURA: (2,3,4) 
                   The pleura transmit the force produced   by the respiratory muscles to 
the lungs. During normal respiration there is a negative pressure to atmosphere 
within the pleural cavity. This will suck capillary fluid and gas from the 
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surrounding tissue into the cavity. There is a hydrostatic pressure difference 
between parietal pleural capillaries and visceral pleural capillaries supplied. Plasma 
oncotic pressure is similar in both capillaries. Pleural osmotic pressure is only about 
0.8kPa since little protein   is   able to escape from the adjacent healthy 
capillaries.(2) Therefore   there is net force which  derives Pleural fluid into 
lymphatics and  visceral capillaries.  Low-protein fluid is transferred from parietal 
to pleural space regularly.(2) Reabsorption  occurs through the lymphatic vessels 
opening into the Parietal pleura.(2)  
                  The pleural fluid is in a dynamic state. Every hour 30- 70% of the water 
is being turned over. Increased lung movement such as exercise accelerates this 
turnover.   Protein and other particles are turned over   less rapidly.  Proteins and 
others are absorbed only by lymphatics. Any condition that causes inflammatory or 
neoplastic change in the parietal pleura can lead to decrease protein reabsorption. 
This causes alteration of the fluid hydrodynamics. This will eventually leads to 
increase the size of the effusion. 
PATHOPHYSIOLOGY: (2, 3, 4, 6, 7) 
                   Pleural effusion is an indicating symptom of   underlying pathologic 
conditions. These conditions   may be of primary pulmonary origin, origin from the 
other organ system or to a systemic disease. It is not a diagnosis in itself. It may 
occur in the presentation of acute or chronic disease.(2)                 
                     The following  are characteristics of normal pleural fluid: clear 
ultrafiltrate  of plasma, pH 7.6 – 7.64, Protein concentration less than 2%   (1-
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2g/dl), less  than 1000 WBCs / cubic ml, glucose concentration  similar to  of 
plasma, lactate dehydrogenase level less than 50% of Plasma. Potassium, calcium 
and sodium concentration similar to the interstitial fluid.(2) 
                    The   primary function of the pleural fluid is to give a frictionless 
surface between the two pleural membranes in reaction to changes in lung volume 
with respiration. The mechanisms involved in the formation of pleural effusion are 
as follows.  
• Alteration in the pleural membranes permeability (neoplastic disease, 
inflammatory process). 
• Reduced intravascular oncotic pressure (e.g, hepatic cirrhosis 
hypoalbuminemia). 
• Increased capillary permeability (e.g neoplastic disease, infection, 
inflammatory process, trauma, pulmonary infarction, drug 
hypersensitivity). 
• Increase hydrostatic pressure in the systemic and pulmonary circulation 
(e.g Congestive heart failure). 
• Reduced pressure in pleural cavity so lung is unable to expand (e.g 
extensive atelectasis). 
• Inability of the lung to expand (e.g extensive atelectasis,   
mesothelioma). 
• Decrease in the lymphatic drainage including thoracic duct obstruction 
or rupture (malignancy, trauma). 
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• Increased fluid in the peritoneal cavity - migration across the 
diaphragm through lymphatics (peritoneal dialysis). 
• Movement of fluid from the pulmonary edema across the visceral 
pleura 
• Iatrogenic (Central line displacement). 
   Morbidity and mortality of pleural effusion are directly due to cause, 
stage of disease at the time of presentation, and biochemical values   in the 
pleural fluid. 
• Morbidity and mortality rates of patents with pneumonia and 
pleural effusion are higher than those of patients with 
pneumonia alone. 
• Development of a malignant pleural effusion is associated with 
a poor prognosis. The average life expectancy of a patient after 
a diagnosis of malignant pleural effusion is 3-6 months. 
• With malignant mesothelioma, the outcome depends on the 
pathologic stage at the time of presentation. 
CLINICAL FEATURES: (4) 
                                               The clinical manifestations of pleural effusion are variable. They are 
related to the underlying disease. The most common symptoms associated are 
progressive dyspnea, cough (typically non productive) and pleuritic chest pain. 
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 Dyspnea 
           - Dyspnea is the most common clinical symptom at presentation.  
           - It indicates a large effusion (usually not < 500 ml). 
            - It is reported to occur n 50% of patients with malignant pleural effusions. 
 
Chest pain 
- Chest pain - mild or severe, described as sharp or stabbing.  
- Pain - localized to the chest wall or referred to the ipsilateral shoulder 
or upper abdomen   mostly because of diaphragmatic involvement. 
- It   diminishes in intensity as the effusion increases in size. 
Other   signs and symptoms   of   Pleural effusions are due to the underlying 
disease.(2) 
- Increasing lower extremity edema, orthopnea and paroxysmal nocturnal. 
dyspnea all may occur with congestive heart failure. 
- “Night sweats, fever, hemoptysis and weight loss may occur with 
TB”.(2) 
- An   acute   febrile episode, purulent sputum production, and pleuritic 
chest pain may occur in patients with an effusion associated  with 
aerobic  bacterial pneumonia.(2) 
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PHYSICAL EXAMINATION: 
                  Physical findings are variable and depend on the volume of the effusion. 
“Generally findings are undetectable for effusion smaller than 300ml.(2)” With an 
effusion larger than 300 ml, physical findings often may include the following. 
- Dullness or decreased resonance to percussion. 
- Diminished or inaudible breath sounds. 
- Decreased tactile fremitus. 
- Egophony at the most superior aspect of the pleural effusions.  
- Pleural frictions rub.  
- Asymmetric expansion of the thoracic cage, with lagging expansion on 
the affected side. 
- Mediastinal shift – seen with massive pleural effusions. 
- Noted in chest x ray as displacement of trachea and mediastinum to the 
contra lateral side. 
Other physical findings for pleural effusion. 
               -   Anasarca. 
- Cutaneous changes of chronic liver diseases.  
- Distended   neck veins. 
- Breast nodule or intra abdominal mass. 
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CAUSES OF PLEURAL EFFUSION: 
                  Classification of pleural fluid is depending on the mechanism of fluid 
formation and pleural fluid chemistry. Pleural effusions are mainly categorized into 
transudative and exudative pleural effusions.  
Pleural transudate: 
       Most common cause is congestive cardiac failure. It is often unilateral, 
usually on the right side. In severe failure it is usually bilateral. Increased 
transudation of fluid from the lung is the mechanism, partly as a result of increased 
capillary pressure.  Increased pulmonary interstitial pressure also can cause 
transudate.(2) The diagnosis  can be obvious  from associated  clinical features. 
Diagnostic aspiration can be omitted until after a trial of diuretic treatment. 
 Causes of pleural transudates 
                    Table. 1 Causes of Pleural transudates 
Increased hydrostatic pressure: 
• Congestive cardiac failure. 
• Constrictive  Pericarditis 
• Percardial effusion 
• Constrictive cardiomyopathy 
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• Massive Pulmonary embolism.    
Decreased  capillary oncotic pressure  
• Cirrhosis 
• Nephrotic syndrome 
• Malnutrtion 
• Protein losing enteropathy 
• Small bowel disease 
Transmission from peritoneum 
• Any cause of ascitis  
• Peritoneal dialysis  
• Liver transplantation 
Increased  capillary permeability 
• Small pulmonary emboli 
• Myxodema     
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                              Table -2 . Pleural exudates  
Neoplasms 
           Mesothelioma, very rarely Pleural sarcoma 
 Metastases 
 Lymphoma 
Infections 
Pneumonia, abscess                                            
Tuberculosis 
AIDS 
Fungal and actinomycotic disease 
Hepatic amoebiasis  
Immune disorders 
            Post myocardial infarct 
            Rheumatoid disease 
            Systemic lupus erythematosus 
            Rheumatic fever 
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Abdominal diseases 
             Pancreatitis 
             Uraemia 
             Other causes of peritoneal exudates 
Other causes 
              Pulmonary embolism and infarction 
              Sarcoidosis 
              Drug reactions 
              Asbestos exposure 
              Recurrent Polyserositis 
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Pleural exudates: 
                  The common causes are metastatic tumour, infections and pulmonary 
embolism. 
Neoplasms: 
                 “A Primary Pleural tumour is almost always a mesothelioma”.(2) 
Metastasis occurs  mostly from bronchial, breast, stomach and ovarian carcinoma.  
Any other malignant neoplasm can metastasize to   Pleura occasionally. Lymphoma 
causes effusion without necessarily causing pleural infiltration. “Malignant pleural 
effusions are mostly blood stained and recur after aspiration”.(2) 
Infections: 
                  Bacterial pneumonia is associated with pleural effusion in about 40% of 
cases.  The effusion may be amber coloured in the initial stage.  It may progress to 
increased turbidity with a high white cell count. Viral and mycoplasmal pneumonias 
rarely cause effusion. Tuberculosis remains an important cause of Pleural effusions. 
        The effusion associated with Pneumonia is initially sterile. It may 
frequently invaded by the causative microbes. It leads to empyema or eventual 
healing by fibrosis.  That is why, aspiration to dryness is needed at the time of 
presentation. It is not wise to expect resolution of effusion with the antimicrobial   
for the Pneumonia. 
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Tuberculous pleural effusion(2): 
       Pleural effusion may occur as a complication of tuberculosis in four 
situations. This   is due to actual infection of the pleura by tubercule bacilli.  
Tuberculin hypersensitivity probably plays a part in   the reaction. 
                  1. Effusion may occur due to primary tuberculosis in children when the 
peripheral site or caseating lymphnode ruptures into the pleura. This disease 
typically present within the age of 5 and puberty and occurred in about 7% of 
patients with primary tuberculosis. The effusion occurs 3-6 months after infection 
usually. It is associated with general tiredness, fever and pleuritic chest pain. The 
effusion resolves without treatment in 3-4months. Sometimes leaves only some 
blunting of the costophrenic angle and evidence of primary complex.  This 
syndrome is seen more frequently in middle aged and elderly individuals nowadays 
who may have lost their tuberculin sensitivity. At presentation they may have 
negative tuberculin test sensitivity, though these invariably become positive within 
a few weeks.(2)  
                  2. Pleural effusion may present in adolescents after few weeks of 
malaise with   pleuritic pain and fever. This condition became much less common 
after BCG vaccination. The illness can manifest initially with recurrent dry pleurisy 
and all evidence of disease may appear without treatment over a few months.(2) Up 
to 2/3rd of these patients develop active pulmonary TB within the ensuing 5years.  A 
proportion of patients, treatment is started late or withheld because of diagnostic 
uncertainty progress to pleural fibrosis.  This can cause serious restrictive 
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impairment of lung function.  This kind of patients finally require surgical 
pleurectomy.(2) Early diagnosis and treatment is therefore important.(2) 
                  3. This type of tuberculous effusion is relatively rare.  It occurs if a 
tuberculous cavity in individuals with extensive post primary disease ruptures into 
the pleura. This causes a tuberculous pyopneumothorax . The patient becomes 
breathless and complaining of pleuritic pain.  There is an increase in malaise and 
fever. Bronchopleural fistula may result and causes considerable management 
problems. A fatal outcome is frequent in this condition. “When resolution takes 
place, chronic fibrothorax is almost always the result with extensive calcification”. 
Before the modern era of antibiotics, this was often the outcome of pleural effusion 
complicating artificial pneumothorax treatment for tuberculosis.(2) 
                 4. Pleural effusion is also a manifestation of disseminated tuberculosis in 
patients with AIDS. These types of patients are very ill usually and deteriorate 
rapidly. “The effusion may contain large numbers of bacilli, although the typical 
granulomatous histological changes are often absent.”(2) 
                 The effusion in tuberculosis is rarely massive. “The fluid is usually 
serous and contains more than 50g/L protein with a predominant lymphocytosis.”(2) 
Tuberculin test is usually positive in immunocompetent people. In the early stages it 
may be negative sometimes, so, it should be repeated 1month later.  The earlier 
negativity may be due to the circulating lymphocytes that suppress the activity of 
tuberculin-sensitized T lymphocytes. “Culture of pleural fluid is often negative.” 
The chances of a positive result being increased in proportion to the amount of fluid 
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sent to the laboratory.  Pleural biopsies show granulomas in about two-thirds of 
patients. In some instances repeating the biopsies and culture shows the increased 
rate of diagnosis to 90%.(25) 
                 Infection with the other pathogenic mycobacteria has been recognised 
more frequently as the incidence of tuberculosis has declined now. NTM are a well-
recognised in the immune suppressed. Pleural effusion occurs in about 5% of cases 
usually in association with radiological evidence.(2)   
Immune disorders: 
                  Rheumatic fever occurs commonly in India. Annual incidence of about 
0.5 per 1000 children. It may be accompanied with pleurisy   usually accompanied 
by pericarditis.(2)  
                  Rheumatoid arthritis may be associated with effusion in about 15% of 
males with the disease but only 2% of females.  The effusion occurs within about 5 
years of the start of the disease in patients with severe arthritis and subcutaneous 
nodules. The effusion can be an incidental finding or may accompany worsening 
arthritis and increased systemic symptoms. The fluid is straw coloured. It has a low 
glucose and PH and a high lactate dehydrogenase. “Rheumatoid factor and Immune 
complexes may be found in Pleural fluid, often at higher titres than in blood”. 
“Biopsies of Pleura may show typical rheumatoid histology”.  Thoracoscopy shows 
a highly characteristic granular appearance to the Parietal pleura.  The granular 
changes is due to palisaded  epithelioid cells and occasional gaint cells, resembling 
an opened out rheumatoid nodule(2). These nodules may be responsible for the 
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production of the immune complexes often found in the fluid. The condition usually 
regresses gradually and eventually clearly established. “Chronic persistence of the 
effusion or progressive pleural fibrosis may lead eventually to the need for 
Pleurectomy”. Occasionally the condition may be bilateral and associated with other 
pulmonary manifestation of rheumatoid disease. There also appears to be a risk of 
infection of these effusions, leading to empyema(2). 
                  Systemic lupus erythematosus presents frequently with pleurisy. In 
contrast to rheumatoid pleurisy SLE is more common in women than men. The 
usual presentation is bilateral small effusions.  Lupus cells may be demonstrated in 
the fluid as well as the blood and a high titre of antinuclear antibodies in the fluid is 
diagnostic. The fluid is often blood stained and tends to have a normal glucose and 
low lactate dehydrogenase. Effusions can occur in lupus secondary to other 
complications of the disease (uraemia or Pneumonia). The lupoid effusion rarely 
resolved spontaneously. It usually has good response to corticosteroid treatment. If 
this fails, Cyclophosphamide may be necessary.(2) 
                  Other collagen disease seems rarely to be associated with pleural 
effusion unless associated with lupoid features or as a complication of renal or 
cardiac failure or of pulmonary infection. Wegener’s granulomatosis of the lung 
may be complicated by pleural effusion. This effusion is minimal and responds to 
treatment.(2) 
                 The Post – cardiac injury syndrome, a relatively uncommon complication 
of myocardial infarction or cardiac surgery. It is characterized by malaise, fever and 
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pleural and pericardial pain usually coming on about 3 weeks after the cardiac 
injury.  Effusions may occur in pericardium and pleura and pulmonary infiltrates 
may be seen, the fluid is mostly bloody and with high glucose and PH.  It is difficult 
to differentiate the condition from pulmonary infarction. It usually responds to 
Corticosteroid treatment.(2)   
Invesitagation: (4,5) 
                  After diagnostic pleural tap biochemical, cytological and 
microbiological examination of the pleural fluid is to be done. The first important  
step in analysing pleural fluid is to determine the  effusion is a  transudate or an 
exudate.   “Light’s criteria” is used to detect exudative pleural effusion. If one or 
more of the following is met, it is exudative.(5) It is transudative if  none are met. 
“ Light’s Criteria”(33): 
 Pleural fluid 
• Serum protein ratio > 0.5. 
• Serum LDH ratio > 0.6. 
• LDH > 2/3 upper limit of normal serum LDH.  
• Protein > 30 g/l. 
These criteria are   less accurate for transudates caused by CCF. The use of 
diuretics has been shown to increase the pleural fluid protein and LDH. 
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                 The minimum volume of pleural fluid required for basic diagnostic 
purposes is 20ml, if possible, 60 ml should be obtained for potential diagnostic 
studies.(3,4,5) 
I. If clinial presentation is highly suggestive of transudate effusion 
mainly Protein and LDH levels should be tested. Concomitant 
serum total protein and serum LDH should be done. Serum 
albumin should be done if indicated. No further testing needed for 
transudative effusions.(3,4) 
II. Exudative pleural effusion requires further laboratory testing. The 
following should be done.(3,4,5) 
a. Cell count with differential count 
b. Total protein level. 
c. Glucose level 
d. LDH level 
e. Amylase level. 
f. PH 
g. Cytological analysis  
h. Gram staining, Acid fast staining, KOH 
mount, Culture and sensitivity testing for 
bacteria and Fungi 
i. Blood culture. 
j. Determination of serum total protein, 
glucose, LDH and amylase level. 
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III. Additional studies required on the basis of the gross appearance of the 
pleural fluid. The colour, turbidity, viscosity and odour are 
essential characteristics. 
      Table-3 Macroscopic examination of Pleural fluid 
S.NO Characteristics Significance 
1 Bloody Most likely an indication of 
malignancy  
2 Turbid Increased cellular content or lipid 
content 
3 Yellow or whitish, turbid  Presence of chyle, cholesterol or 
empyema 
4 Brown, chocolate sauce, 
ancovy paste 
Rupture of ameobic  liver abscess into  
the pleural space  
5 Black Aspergillus involvement of Pleura 
6 Yellow collor with debris   
Rheumatoid pleurisy 
7 Highly viscous Malignant mesothelioma, long 
standing pyothorax 
8 Ammonia odour Urinothorax 
9 Purulent Empyema 
10 Yellow and thick, with 
metallic sheen 
Effusions rich in cholesterol. 
(tuberculous or rheumatoid pleuritis) 
 
25 
 
IV. Other parameters of pleural fluid analysis(2,3.4,5) 
                            Table-4  Biochemical analysis of Pleural fluid 
1 Amylase Elevated in acute pancreatitis, pancreatic 
pseudocyst, esophageal rupture, malignancy and 
ruptured ectopic pregnancy. 
2 Glucose A low glucose level seen in TB, malignancy, RA, 
empyema, hemothorax. 
3 PH < 7.2 in empyema, PPE, esophageal rupture, RA, 
malignancy, TB, urinothorax. 
4 LDH Is an indicator of the degree of pleural 
inflammation. Higher values in PPE.  
5 RBC count >105 indicate trauma, malignancy, pulmonary 
embolism, injury after cardiac surgery. 
6 Total WBC count  Not useful. 
7 Neutrophil count 
 
Eosinophil count 
 
 
Lymphocyte count 
 
Increased in acute inflammatory process. 
Increased in pneumothorax, haemothorax, 
pulmonary infarction, prior thoracocentesis,  
paragonimiasis, hydatid disease, amebiasis, 
ascariasis,  drugs- nitrofurantoin. 
Increased in malignancy or TB. 
8 Plasma cell  Multiple myeloma. 
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V.Adenosine Deaminase activity:(5,34) 
                  “ADA is an enzyme involved in purine catabolism”. ADA is present in 
most of the cells particularly present in lymphocytes. ADA concentration inversely 
related to the degree of differentiation.(34) High levels of  ADA have been found in 
patients with lung cancer and tuberculosis.(5,35) Levels of ADA activity show a 
significant correlation with the number of CD 4 cells in the pleural effusion. 
VI. Chest radiography: (4)  
                  The most common radiological appearance is blunting of the 
costophrenic   angle and sulci. As fluid accumulates blunting becomes more 
pronounced and an upward concave meniscus seems to ascend the lateral chest wall, 
this is called meniscus sign. Mostly seen as generalized homogenous opacity and 
diffuse haziness as the fluid forms layers  posteriorly, visibility of  pulmonary 
vessels through haziness, and an absence of air bronchogram.(4) 
I. The location of the Pleural effusion can help in the differential diagnosis 
                  Isolated Right sided -   commonly occurs in cirrhosis, peritoneal 
dialysis, subphrenic or intra hepatic abcess , amebic liver abcess, Meigs 
syndrome.(4) 
                  Isolated Left sided -  Esophageal rupture, pancreatic  disease, 
subphrenic or splenic abcess, splenic infarction, diaphragmatic hernia.(4) 
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                 Bilateral – All Malignancies except Lung and breast has unilateral 
effusions. (4) 
 
VII. Ultrasonography 
                  It can be used to detect as little as 5- 50ml of pleural fluid, with 100% 
sensitivity for effusions of 100 ml or more.(4) 
VIII. Chest CT scanning: 
                  CT scan permits imaging of the pleural space, pulmonary parenchyma 
and mediastinum simultaneously.(4) 
IX. Other imaging studies include MRI and nuclear scanning, Ventilation – 
Perfusion scanning. 
THORACOCENTESIS: 
                Thoracentesis is the least invasive procedure and it is relatively safe. 
Indications:(4) 
                Respiratory compromise, hemodynamic instability or massive pleural 
effusion with contralateral mediastinal shift and if specific cause of effusion 
unknown. 
                 In patients with CCF thoracocentesis is done for the following conditions 
– fever, unequal effusions and absence of cardiomegaly. 
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Contraindication:  
                   No absolute contraindication except very minimal fluid effusion. 
Relative contraindication: 4  
                   Hemorrhagic disorders, iatrogenic systemic anticoagulation (particularly 
with thrombolytic agents), cutaneous disease or pyoderma at the needle entry site 
and uncooperative patients. 
Complication of Thoracocentesis: 
 Pneumothorax, subcutaneous hematoma, infection. 
Treatment: 
                   Treating the underlying cause is the mainstay of management. 
Therapeutic tapping needed for massive pleural effusion to relieve symptoms. 
Infective effusions should be treated with appropriate antibiotics and tube drainage   
may be necessary. Tuberculous effusions require antituberculous drugs and 
corticosteroids. Corticosteroids   speeds reabsorptions and prevents pulmonary 
fibrosis.(4) 
Complications:(4) 
                   Delaying diagnostic thoracocentesis and antibiotic therapy for 
parapneumonic effusion increases the risk of empyema, pulmonary  fibrosis and 
sepsis. 
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Prognosis: 
                  Prognosis varies and depends on the cause and characteristics of the 
pleural effusion. Patients who seek medical care earlier in the course of their disease 
and those with prompt diagnosis and treatment have a substantially lower rate of 
complications than who do not. 
BACTERIOLOGY OF    PLEURAL EFFUSION: (23) 
                 The microbiology of empyema has changed dramatically in the last 
50years. In the preantibiotic era, Streptococcus pneumoniae accounted for   60% to 
70% of cases, Streptococcus pyogenes for 10% to 15% of cases, and 
Staphylococcus aureus for 5% to 10% of cases. S. pneumonia more recently 
accounts for only 5% to 10% of cases. (23) 
                  Many infections are mixed, with anaerobes present in 25% to 76% of 
empyemas as sole organisms or in combination with other aerobic or facultative 
organisms. Without prior antibiotic therapy or surgical procedure pleural empyema 
was   caused by aerobic bacteria in 24%, anaerobic bacteria in 35%, and both   
aerobic and anaerobic bacteria in 41% of patients. 
                  The most common anaerobes isolated include the Bacteroides fragilis 
group, Prevotella species, Fusobacterium nucleatum, and what was then called as 
Peptostreptococcus and would likely now be identified as Feingoldia. Pleural 
infection disease is often polymicrobial and anaerobic in origin. (23) 
                  Several recent studies have reported a shift from traditional pathogens to 
the Streptococcus anginosus group (formerly termed Streptococcusmilleri) in 
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community-acquired disease, especially in patients with comorbidities. In a large 
study from Canada, the Streptococcus anginous group   (S. anginosus, S. 
intermedius, and S. constellatus)   was recovered in 50% of proven empyemas in 
patients with community- acquired pneumonia;   50% had a coexisting condition.  
S. anginosus group was also the most common organism cultured in community- 
acquired  empyema in the Multicenter Intrapleural Sepsis Trial (MIST 1) performed  
in 52 centers in the United Kingdom.(12,23)  In addition, up to 25%of community-
acquired empyemas culture anaerobic bacteria. Over 65% of patients had a 
coexisting condition.  By contrast, hospital acquired empyema include more 
staphylococcal infections (mostly caused by methicillin-resistant Staphylococcus 
aureus [MRSA]) and gram-negative organisms. Anaerobes were only recovered in 
5%. Predisposing factors are most important in predicting the most likely 
pathogens. (12,23) 
 
                   Pneumonia continues to be the most frequent predisposing factor in the 
development of empyema. In otherwise healthy adults with pneumonia, the most 
common bacteria causing pleural empyema are S. aureus, S. pneumoniae, or S. 
pyogenes. The incidence of a parapneumonic effusion in hospitalized patients is 
estimated to be 40%. Although S. pneumoniae is the most common cause of 
community- acquired pneumonia, empyema has occurred in only 1% to 2% of cases 
of pneumococcal pneumonia compared with 10%to 18% in the preantibiotic era. 
Empyema caused by S. aureus, S.pneumoniae,or Haemophilus influenzae has been 
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common in children. The H. influenzae conjugate vaccine has dramatically reduced 
the frequency of suppurative complications caused by H. influenza. 
                  Most cases of S. aureus empyema result from S. aureus pneumonia, 
which is most often seen in older hospitalized patients with underlying medical 
problems. S. aureus is an uncommon cause of pneumonia in otherwise healthy 
adults, except during an influenza outbreak. (12,23) 
                       
                 S.aureus has a tendency to cause cavitation, with resultant secondary 
lung abscesses. Empyema can be seen in 10% to 24% of adults with S. aureus 
pneumonia. In children, multiple thin-walled cavities or abscesses, or 
pneumatoceles, develop with S. aureus pneumonia.(23) 
                  S. pyogenes was a common cause of pneumonia in the preantibiotic era, 
but cases are uncommon today. S. pyogenes pneumonia can be seen in military 
recruits or as a sequela of a viral respiratory infection.  Empyema occurs in 30% to 
40% of cases and tends to develop early in the course of infection.(12,23) 
                  Factors predisposing to aspiration, such as altered mental status, 
alcoholism, and periodontal disease are common in patients with anaerobic 
infections of the pleura.   Many of these cases tend to be polymicrobial.  In addition 
to anaerobes, viridans group streptococci, aerobic gram-negative bacilli, and 
occasionally S. aureus have been recovered.(23) 
                 Viridans streptococci are normally found in the mouth and 
gastrointestinal 
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tract. A study of pulmonary infections caused by viridians streptococci found that 
most (68%) of the isolates belonged to the S. anginosus group.  Many of the S. 
anginosus group isolates, particularly those of Streptococcus intermedius, are 
nonhemolytic, but some are α- or β-hemolytic, and most carry Lancefield group F 
antigen. (12,23) 
                 Isolates in the S. anginosus group are known by their propensity for an 
invasive pyogenic process that results in abscess formation; this is attributed to their 
ability to produce hydrolytic enzymes that facilitate the spread and liquefaction of 
pus.  Pleuro pulmonary actinomycosis can result from aspiration. These patients 
exhibit a chronic pulmonary infection with chest wall involvement or draining sinus 
tracts with sulfur granules, or both. Up to 50% of pulmonary actinomycosis have 
pleural involvement. Isolation of Actinomyces from a normally sterile site confirms 
the diagnosis. (23) 
                  Legionella can be isolated from parapneumonic effusions. These 
effusions tend to be small and usually do not progress to empyema(23). 
                  Mycoplasmal and viral infections can also produce small effusions that 
usually resolve spontaneously. (23) 
 
                  In many parts of the world, tuberculous effusions are common, and they 
can be secondary to a primary infection or occur as reactivation of tuberculosis. In 
most cases, tuberculous effusions resolve spontaneously; however, up to 50% of 
patients not treated with appropriate anti tuberculous medication will develop active 
tuberculosis within 5 years. (25) 
33 
 
                  There is a high frequency of S. aureus and aerobic gram-negative 
bacillary infection in patients with empyema after trauma or surgery. (23) 
                 Empyema complicating hemothorax is often staphylococcal, whereas 
associated with pneumothorax or hematogenous seeding of a serous effusion is 
often caused by aerobic gram-negative bacilli.(23,25) Several studies have indicated 
an increased risk of post-traumatic empyema associated with retained hemothorax 
and significant pulmonary  contusion. 
                  Mixed oropharyngeal organisms and occasionally Candida species are 
the organisms most frequently cultured from pleural fluid after esophageal rupture. 
Cultures obtained after sub diaphragmatic extension of an intra-abdominal infection 
usually show mixed enteric gram negative  bacilli, anaerobes, and Candida(23). 
                  Although fungal infections of the pleural space are uncommon in the 
normal host, there has been an increase in fungal empyemas, and most are caused 
by Candida species.(23) Candida empyema has been  reported as a complication of 
surgery, a result of esophageal rupture,  a sub diaphragmatic infection, and being 
spread hematogenously.(23) Many of these infections are polymicrobial.(23) 
                  Amoebic liver abscess is associated with pleural involvement in up 
to15% to 20% of cases. Two mechanisms have been identified. First, amaebic liver 
abscess can irritate the diaphragm, producing a sympathetic pleural effusion. 
Second, a complex pleural effusion can develop when the amoebic liver abscess 
ruptures into the pleural space through the diaphragm.(23) 
                 Immunocompromised patients have a higher frequency of empyema 
caused by fungi and gram-negative bacilli. Organ transplant recipient patients with 
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acquired immunodeficiency syndrome (AIDS) may reactivate pleural foci of 
mycobacterial or fungal infection, but they rarely present with empyema without 
disseminated disease. Unsuccessful resection of cavitary coccidioidomycosis or 
aspergillosis may be complicated by empyema and bronchopleural fistula from that 
organism.(23) 
                   Nocardia infections occur more frequently in patients with   underlying 
conditions, such as organ transplantation, malignancy, diabetes mellitus, AIDS, and 
long-term use of steroids.(23) Pleural effusions   can develop in up to 50% of 
patients.  Nocardia infections occur more frequently in patients with underlying 
conditions, such as organ transplantation, malignancy, diabetes mellitus, AIDS, and 
long-term use of steroids. Pleural effusions can develop in up to 50% of patients 
with nocardiosis.(23) 
Clinical Features and Diagnosis of Tuberculous Pleurisy (25): 
                 The clinical presentation may be low grade and subtle or abrupt and 
severe, easily confused with acute bacterial pneumonia. Cough and pleuritic chest 
pain are usual, and fever may be high. The effusion is usually less than massive and 
almost always unilateral except when associated with miliary tuberculosis. The 
pleural fluid typically contains 500 to 2500 white blood cells/mm3, with more than 
90% lymphocytes in two third of cases. However, 38% of cases in one series had 
predominantly neutrophils, and 15% had more than 90% neutrophils on the first tap. 
Repeated taps demonstrate a shift to lymphocytic predominance. Mesothelial cells, 
characteristic of neoplastic   effusions, are sparse or absent, eosinophils are rarely 
present, and less.(25) 
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Diagnosis of Tuberculous pleural effusion: 
                  Pleural tuberculosis can be diagnosed by stains of pleural fluid in only 
18% to 23% of patients, but cultures of pleural fluid and histologic examination of 
pleural biopsy specimens permit the diagnosis in up to 95% of patients.  
 
  Table.5. Diagnostic values of pleural fluid ADA, Pleural fluid culture, Pleural 
biopsy and    culture (25). 
 Invasiveness Sensitivity Specificity 
Pleural fluid ADA Less invasive 90% Less* 
Pleural fluid culture Less invasive 10- 47% More 
Pleural biopsy 
tissue culture 
More invasive 56 – 82% More 
Pleural biopsy 
tissue Histology 
More invasive 39- 84% more 
 
*- In areas where Tuberculosis is prevalent ADA value is both sensitive and 
specific. ADA estimation can be used as early screening test.(17,!8)  
 
                  Liquid culture media are preferable to solid   culture media.(25)  
Radiometric culture may increase the speed of diagnosis in patients with pleural 
tuberculosis.(25,16)  
                  Three other diagnostic tests   are available to help establish the diagnosis 
of tuberculous pleural disease—tests for adenosine deaminase (ADA) and 
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interferon-γ, and the polymerase chain reaction (PCR) assay. In one study, pleural 
fluid ADA levels above 40 U/L were found in 99.6% of patients with tuberculous 
pleurisy.(17,18)   An  elevated  level of interferon –γ of 140 pg/mL  is comparable to 
an elevated level of ADA for diagnosing tuberculous  pleurisy(25).  The results of 
using PCR   to detect Mycobacterium tuberculosis DNA in pleural fluid have 
varied.(25) 
                 In one study, PCR was as sensitive as the ADA test but in another study, 
the sensitivity of PCR was only 42%. Two tests for M. tuberculosis nucleic acid are 
commercially available and, although approved only for respiratory specimens, can 
be used on non respiratory specimens, such as pleural fluid. Increased risk of 
exposure to tuberculosis, host defensive defects favouring reactivation, skin test 
conversion, or symptoms of weight loss, night sweats, and fever are helpful clues to 
the diagnosis of tuberculosis.(25) 
 
Broth media 
                   Broth media   (eg, Middlebrook 7H9 and 7H12) support   the 
proliferation of small inocula. Ordinarily, mycobacteria grow in clumps or masses 
because of the hydrophobic character of the cell surface. If tween (water-soluble 
esters of fatty acids) are added, they wet the surface and thus permit dispersed 
growth in liquid media. Growth is   often more rapid than on complex media.(24) 
There are several commercial   sources of these media that are used in many clinical 
and reference laboratories.   These include the MGIT system (Becton Dickinson, 
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Sparks, MD), versa TREK Culture System. Broth is used for drug susceptibility 
testing in resource poor settings.(36) 
 
Identification of   M.tuberculosis and NTM: 
                  The   following tests used in combination to differentiate M.tuberculosis 
from other Mycobacteria. The   characterstics described below will enable the 
precise identification of > 95% of   M.tuberculosis strains (26).  
1. Susceptability to para – nitro benzoic acid(26,30) 
2. Niacin Test(26,30) 
3. Catalase Activity at 68 ̊c / pH 7.(26 ,30) 
4. MP T 64 Ag test .(27,28) 
Table 6 Identification of Mycobacterium spp. 
S.NO Tests M.tuberculosis NTM or MOTT 
1 Growth in PNB Negative positive 
2 Niacin test Positive Negative 
3 Catalase activity at 68 ̊c  Negative Positive 
4 MPT 64 Ag test Positive Negative 
 
MPT 64 antigen: 
                   M.tuberculosis   secretes more than 33 different proteins.  MPT 64 was 
found to be predominant in the culture fluid of only strains of the M.tuberculosis 
complex.(27) 
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MPT 64 Ag Rapid test: 
                 This is an   immuno chromatographic assay.   
Principle: 
                  This test cassette contains a sample pad, a gold conjugate, a 
nitrocellulose membrane and an absorbent pad.  First monoclonal antibody labelled 
by colloidal gold particles reacts with MPT 64 antigen in sample to form antigen –
antibody complex. Complex is then captured by a second monoclonal antibody 
fixed in the middle of the test zone. Results available within 15 mins.(27) 
 
Limitations of the test: 
                     -   This test does not differentiate between members of the MTBC. 
                      -  Requires culture (no direct inoculation from clinical specimen). 
                      -   Some strains of M.bovis BCG are interpreted as negative (organism 
lacks MPB64). 
                        -  Strains of microbes such as S.aureus, which produce protein A 
may produce a false positive result. 
                       - Negative test results can occur if the MPT 64 concentration in the 
culture sample is below the detectable limit.(27) 
                                          
 
 
 
  
 
MATERIALS AND 
METHODS 
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                                       MATERIALS AND METHODS 
ETHICAL CONSIDERATION: 
                   Ethical   clearance was obtained from Intuitional Ethics Committee 
before starting the study. 
STUDY DESIGN   :    Cross sectional study. 
STUDY PERIOD   :    October 2014 to September 2015. 
STUDY SETTING :  
                  The study   was conducted in the Institute of Microbiology in association 
with Institute of   Internal Medicine, Institute of Thoracic Medicine, Madras 
Medical College& RGGGH. All patients satisfying the following inclusion criteria 
were documented. 
INCLUSION CRITERIA: 
                  Patients with diagnosis of Pleural effusion.   
                  Age above 18 years. 
EXCLUSION CRITERIA: 
                    Patients   age   below 18 yrs. 
METHODOLOGY: 
       Informed consent   was   obtained   before   diagnostic thoracocentesis.  
Thoracocentesis   was   done   by   physician. 
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Thoracocentesis: 
                    Under aseptic precautions, pleural tapping was done. Lignocaine 2% 
infiltration was given for local anaesthesia. Chest wall was disinfected with 
povidone iodine, after 2mins catheter was inserted through the lower border of ribs 
(6- 9 th ribs) in the lateral side of chest.  Dressing was applied with sterile gauze 
pad. 
                   Pleural fluid was collected   in three sterile test tubes. Immediately 
transported to the lab without any delay.   
Macroscopic examination: 
                 Appearance of pleural fluid was examined and noted.  
- Clear, cloudy or purulent. 
-  Blood stained. 
-  Contains clot. 
Sample processing: 
                  First   two tubes of samples were centrifuged. Centrifugation was done 
at 3000 rpm per minute.  Discarded   the supernatant.(29) From the sediment of  first 
tube Smears for Direct Gram staining and AFB   staining done.( 29,5) 
                   The centrifuged sediment from the Second tube was used for 
inoculation for culture.(5) From the   third tube  Adenosine deaminase  estimation 
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was done. If ADA   values are elevated inoculation was done in Middlebrook 7H9 
broth for Mycobacterial culture. 
 
 
SMEAR PREPRATION: 
                  The    Slides were labelled.  Two smears   were made for each specimen.  
Smears were    made   from the sediment. Allowed it to air dry and heat fixed.  Then 
Direct Gram staining and AFB staining by Ziehl – Neelsen technique was done. 
 CULTURE : 
                  Inoculated the sediment on chocolate agar plate, Blood agar plate, Mac 
conkey agar plate.  
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                Chocolate agar plates were incubated in candle jar at 37 ̊c for 18 – 24 hrs. 
                Blood agar and Mac conkey agar plates were incubated aerobically at 37 ̊c 
for18 – 24 hrs.(5) 
On Day 2: 
                   Colonies in the culture plates examined. Gram staining and further 
biochemical tests were done for identification of the organisms.  
                   If Gram staining showed   Gram positive cocci, further done were, 
- Catalase test. 
- Slide coagulase test. 
- Tube coagulase test. 
- Optochin sensitivity test. 
- Bile esculin azide agar test. 
Table. 7. Test done for GPC and their interpretation: 
 Gram staining Possible organism Tests to confirm 
1 GPC in clusters Staphylococcus aureus Catalase, slide and tube 
coagulase tests, Novobiocin 
test, 
2 GPC in pairs & 
short chains 
Streptococcus 
pneumonia, Strepcoccus 
pyogenes 
Optochin test, Bile solubility 
test. 
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Antibiotic sensitivity Testing 
                 Antibiotic   sensitivity testing was done by Disk Diffusion method 
Inoculum preparation: 
                  Inoculum was prepared by making a direct broth suspension of isolated 
colonies selected from an 18 – 24 hr agar plate. The suspension was adjusted to 
match 0.5 McFarlands turbidity standard. 
Inoculation of Test plates:  
                 Within 15 minutes after adjusting the turbidity of the inoculum 
suspension, a sterile swab was dipped into the adjusted suspension. The swab was 
rotated several times and pressed firmly on the inside wall of the tube above the 
fluid level. This will remove excess inoculum from the swab. 
                  The dried surface of a Mueller Hinton agar plate was inoculated by 
streaking the swab over the entire sterile agar surface. This procedure was repeated 
by streaking two more times rotating the approximately 60 ̊ each to ensure an even 
distribution of inoculums. As a final step the rim of the agar plate also was 
swabbed. Within 5 minutes drugs impregnated disks were applied. 
Antibiotic disk used for GPC: 
                 Amikacin 30 µg. 
                 Ciprofloxacin 5 µg. 
                 Trimethoprim – Sulfamethoxazole 1.25/ 3.75 µg. 
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                 Cefoxitin 30 µg. 
                 Penicillin 10 U. 
                 Erythromycin 15 µg. 
                 Chloramphenicol 30 µg. 
Detection of MRSA: 
                  Staphyloccus isolates were tested for Methicillin resistance by using 
Cefoxitin 30 µg disk. According to CLSI guidelines zone size of  
                                        
≥
 21 mm–Resistant. 
                                        ≤ 22 mm–Sensitive. 
                  E test with Vancomycin  E strip was done test  to  detect  Vancomycin  
resistance. 
E- test : 
                   The Ezy MCTM strip of Vancomycin (Himedia) was used to detect MIC. 
4-5 similar looking colonies were inoculated into 5 ml of Trypticase soya broth and 
incubated for 2 hours. The inoculum was matched to 0.5 Mc Farlands Standard. 
Lawn Culture was made on the Muller Hinton agar with the inoculum. Ezy 
Vancomycin strip was taken by using a  applicator and carefully  placed  on the MH 
agar. The plate was ncubated at 37 ̊c for 48 hrs. 
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                   Staphlococcus aureus – ATCC 25923 was used as the control for the 
test. The MIC was read where the eclipse intersects   the growth.  The interpratation   
was done according to CLSI guidelines. 
                   If Gram staining showed Gram negative   bacilli the following test  were  
done for identification of the pathogen. 
- Catalase test. 
- Oxidase test. 
- Motility.  
- Test for Indole production. 
- MR test, VP test. 
- Citrate utilization test. 
- Urease test. 
- Sugars -- Glucose, Lactose, Sucrose, Maltose, Mannose. 
- OF Glucose. 
- Lysine decarboxylase test. 
- Ornthine decarboxylase test 
- Arginine dihydrolase test.  
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Table. 8. Identification of   Klebsiella: 
Gram staining  Gram negative bacilli 
Mac Conkey agar Lactose fermenting colony, mucoid 
appearance 
Motility Non motile 
Biochemical Reactions Catalase + , Oxidase  _ 
Fermentation  of Glucose: fermented 
Nitrate reduction - positive 
MR – Negative 
V P- Positive 
Citrate  utilization – positive 
Urease production  -positive 
Lysine  decorboxylase - positive 
TSI- Acid / Acid, gas ++ , No H2 S 
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Table. 9. Identification of Pseudomonas: 
MacConkey agar Large spreading Non lactose fermenting 
colonies, with pigmentation and 
metallic sheen 
Gram staining Gram negative bacilli 
Motility Motile 
Biochemical  Reaction Catalase + , Oxidase + 
TSI – Alkaline/ Alkaline , No H2S , No 
gas 
Urease  production -  negative  
Citrate utilization – negative 
PPA -  negative 
OF lactose – negative 
OF maltose – negative 
Arginine dihydrolase -  positive 
 Polymyxin-B  300units  Susceptible 
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Table. 10. Identification of Acinetobacter: 
Mac Conkey agar Non lactose fermenting- faint pink tint 
Gram staining Gram negative  coccobacilli 
Motility Non motile 
Biochemical  Reactions Catalase +, Oxidase – 
TSI – K/K 
Citrate utilization – negative,  
A.baumanni -  C+ 
Urease production  – Negative 
OF glucose- Oxidative 
OF lactose- Oxidative 
Nitrate reduction- negative 
 
Penicllin Resistant 
 
Drug disks used for Gram negative bacilli: 
                 Cefotaxime 30 µg 
                 Amikacin 30 µg 
                 Ciprofloxacin 5 µg 
                 Trimethoprim – Sulfamethoxazole 1.25/ 23.75 µg 
                 Imipenem 10 µg 
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                 Gentamycin 10µg 
                 Piperacillin –Tazobactum 100/ 10µg 
Detection of ESBL: 
Initial screening test: 
                 Standard disk diffusion method using   Cefotaxime 30 µg or Ceftazdime 
10µg disk was done as initial screening test for ESBL.  
                 Cefotaxime       -   ≥ 27 mm zone size– ESBL Producer 
                 Ceftazidme        -   ≥ 22 mm zone size – ESBL producer 
Phenotypic confirmatory test:  
                  Standard disk diffusion method using ceftazidime 30 µg and    
Ceftazidme -clavulic acid 30 /10 µg were done to detect ESBL. 
 Interpratation: 
                  A > 5 mm increase in zone diameter for combination with clavulnic acid 
vs  Ceftazidime zone   is an ESBL producer. 
                 These two tests were performed with quality control strains Klebsiella 
pneumoniae ATCC 700603. 
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Adenosine Deaminase level estimation:  
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ADA level estimation: 
                  Commercial ADA kit    (Diazyme) was used for ADA estimation. This 
kit consists of two reagents and Calibrator.  
Reagent 1 
                 Reagent 1 consist Tris HCl, 4-AA, PNP, XOD, Peroxidase, Stabilizers 
Reagent 2 
                 Reagent 2 consist – Trs HCl, PH 4.0, Adenosine, EHSPT   
                  The assay procedure was done in semi automated analyser in the 
Institute of Biochemistry, Madras medical college, Chennai. 
Procedure: 
                  Add 180 µl of Reagent 1 in an aliquot then add 5 µl of pleural fluid 
sample to it and incubated for 3 mins at 37 ̊c. Then add 90 µl of Reagent 2.  After 5 
minutes the fluid was assayed by semi automated analyser. After 3 mins, result will 
be displayed. For each sample assay procedure time was 8 minutes and measuring 
time by analyser was 3 minutes. Before measuring ADA level for samples for each 
batch Calibration was done with the Calibrator provided with the kit.  Calibration  
procedure is same as that of test procedure  except instead of  5 µl  sample, 5 µl  
calibrator reagent was used. 
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Results: 
                  Results will be displayed as   U/ L. Values range from 0- 30 u/l (Units 
per litre) ADA >30 U/l in Pleural fluid is considered as significant.(5,25,37,38,39) 
Limitations: 
                  If the sample shows ADA value > 200, test should be repeated with 
diluting the fluid with saline before measurement. The result should be multiplied 
by the dilution factor. 
                  If ADA values are elevated, Pleural fluids were inoculated into 
Middlebrook 7H9 broth. 
Inoculation in Middlebrook 7H9 Broth(30):  
                   From the centrifuged   sample, supernatant discarded, from the sediment 
1 ml sample was taken by a new sterile syringe and inoculated in 15 ml of 
Middlebrook 7H9 broth.(31) 
                  Smear from Middlebrook 7H9 broth done and AFB staining done 
weekly for upto 3 weeks.(31) If positive for AFB,    tested   for MPT 64 Ag.(30) If 
AFB smear negative after 3 weeks discarded as negative. 
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MPT 64 Ag test: 
1. Removed the test device from the foil pouch and placed it on a flat dry 
surface. 
2. Added 100 µl of liqud culture (from Middlebrook 7H9 broth) to   the 
sample well. 
3. Results were interpreted within 15 minutes after sample application. 
Interpretation: 
      Positive: 
               The presence of two colour bands. 
      Negative: 
               The presence of only control band   indicates a negative result. 
          
                
                
              
       
 
 
  
 
 
 
 
 
 
 
 
 
RESULTS 
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RESULTS 
                   This study includes 150 patients with   Pleural effusion   those who are 
admitted in the wards of Institute of Internal Medicine and Institute of Thoracic 
Medicine, RGGGH, Chennai. 
 Age distribution:    Table  - 1    Age wise distribution of the patients 
                        
                  
18 – 30 yrs was the common age group affected in the present study.  
 
Age 
(yrs) 
Male Percentage female Percentage Total Percentage 
18- 30  26 17.33 15 10% 41 27.33% 
31- 40  13 8.6 13 8.66% 27 18% 
41- 50 17 11.33 7 4.66% 24 16% 
51- 60 17 11.33 13 8.66% 30 20% 
>60 25 16.66 3 2% 28 18.66% 
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Gender distribution:  
                   Table – 2 Gender distribution.  (n=150)  
S.NO Sex Numbers Percentage 
1 Male 98 65.33% 
2 Female 42 28% 
                         
 
 
               Males   were  affected  more  commonly than female  in the present  study. 
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Side of Pleural effusion 
                   Table-3. Shows frequency of side of effusion (n= 150)   
              
             
 
                 Right sided pleural effusion was common than left sided effusion 
 
S.NO Side of effusion Numbers Percentage 
1 Right 76 50.66% 
2 Left 59 39.33% 
3 Bilateral 15 10% 
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Clinical  Diagnosis: 
                 Patients were categorised according to the clinical diagnosis 
                                               Table- 4   (n= 150) 
S.NO Diagnosis  No of patients Percentage 
1 TB pleural effusion 14 9.33 
2 Para pneumonic effusion 35 24 
3 Hydropneumothorax 2 1.33 
4 CCF 11 7.33 
5 CKD/ CRF 14 9.33 
6 Malignant  pleural effusion 27 16 
7 Post operative patients 10 2.66 
8 Cirrhosis 4 2.66 
9 Pericardial effusion 1 0.6 
10 Pancreatitis 3 2 
11 Others ( SLE, polyserositis, RA, 
RHD) 
31 20.66 
 
                 Mainly divided in 4 categories 1. TB pleural effusion,   2. Parapneumonic 
effusion, 3. Malignant effusion, 4. Others  ( include CKD, CCF, Connective tissue 
disorders). 
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             Chart Shows the frequency of patients according to clinical diagnosis  
 
                  In the  fourth category patients most of them had clinical diagnosis of  
CCF, CKD and connective tissue disorders. Post operative patients (n=10) are   also 
included in the fourth category.  
                  *-  PP effusion -  Para pneumonic effusion 
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Bacterial  isolates: 
                 Among 150 samples 44 samples showed culture positive. 
                              Table -5     Bacterial isolates (n= 44) 
  
numbers Percentage 
1 Staphylococcus aureus 14 31.81 % 
2 K lebsiella pneumoniae 13 29.54% 
3 Pseudomonas aureginosa 6 13.63% 
4 Acinetobacter  baumanni 6 13.63% 
5 Klebsiella oxytoca 2 4.54% 
6 Eshericichia coli 3 6.82% 
14
13
6
6
3
1
Isolates
S.aureus
K.pneumoniae
P.aureginosa
Acnetobacter
E.coli
K.oxytoca
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Exudate vs Transudate: 
                 In the present study exudative pleural effusion are 64. Bacterial growth 
occurred mostly in the exudative pleural effusion. Protein value more than 3.5 mg/l 
is considered as exudates. 
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Bacterial isolates: 
                Gram positive cocci: 
                Among 44 GPC were 14. That 14 were Staphylococcus aureus. 
                                              Table- 6  MSSA and MRSA 
S.NO S. aureus Numbers Percentage 
1 Total 14 100 
2 MSSA 12 85.71 
3 MRSA 2 14.28 
 
 
                 Among 14   S.aureus 2 were MRSA  
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ESBL: 
                                      Table -7  ESBL producers. 
S.NO Organism Total ESBL Percentage 
1 Klebsiella 
pneumoniae 
13 4 30.76 
2 Klebsiella oxytoca 2 2 100 
3 Esherchia coli 3 3 100 
 
13
3
24
3
2
0
2
4
6
8
10
12
14
Klebsiella pneumoniae Escherichia coli Klebsiella oxytoca
Total
ESBL
 
 Among  13 isolated     Klebsiella pneumoniae  4  were  ESBL producer, all 3 E.coli 
and  2 K.oxytoca were ESBL producer 
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Antibiotic sensitivity testing: 
                     Table – 8.  Results of     Antibiotc sensitivity pattern  of S.aureus 
Total- 14 AK Cipro Cotri Erythro peni vanco CK Tetra 
Sensitive 13 12 8 1 4 14 8 8 
Percentag
e 
92.85
% 
85.71
% 
57.14
% 
7.14% 28.57
% 
100% 57.14
% 
57.14
% 
 
                     Table – 9.  Antibiotic sensitivity pattern of K.pneumoniae: 
Total - 13 AK GM Cipro Cotri CTX CA-C Imi PT 
Sensitive 13 11 6 8 9 13 13 13 
Percentage 100% 84.61% 46.15% 61.53% 69.23 100% 100% 100% 
 
                     Table – 10. Antibiotic sensitivity pattern of  K.oxytoca: 
Total -2 AK Gm Cipro Cotri CTX CAC Imi PT 
Sensitive 2 1 1 1 0 2 2 2 
Percentage 100% 50% 50% 50%  100% 100% 100% 
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                     Table – 11. Antibiotic sensitivity pattern of E.coli: 
Total-3 AK GM Cipro Cotri CTx CA C Imi PT 
Sensitive 3 2 0 1 0 3 3 3 
Percentage 100% 66.66% 0 33.33% 0 100% 100% 100% 
 
 
                     Table – 12. Antibiotic sensitivity pattern of Pseudomonas: 
Total- 6 AK GM Cipro CAZ Imi PT 
Sensitive 4 2 3 2 6 6 
Percentage 66.66% 33.33% 50% 33.33% 100% 100% 
 
 
                     Table – 13. Antibiotic sensitivity pattern of Acinetobacter: 
Total-6 AK GM Cipro CAZ Cotri Imi PT 
Sensitive 6 3 3 3 3 6 6 
Percentage 100% 50% 50% 50% 50% 100% 100% 
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ADA   level estimation (n =150 ): 
                In the present study ADA values were normal i.e < 30 u/l in 122 patients.  
ADA values were elevated   > 30 U/lin 28 patients.  
                     Table – 14.  Mean value of ADA among the 4 clinical categories 
S.NO Clinical diagnosis Mean ADA  level 
1 TB pleural effusion 80.45 
2 Malignancy 28.085 
3 Parapneumonic effusion 20.18 
4 Others 18.441 
 
                 AFB staining by Ziehl Neelsen method was  done for all 150 samples  . 
Among 150, 10 samples were positive  for AFB 
                           Table -15. Correlation of AFB   smear -   ADA  values: 
AFB Smear ADA  Increased Normal 
Smear positive 10 O 
Smear negative 18 122 
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All    ADA elevated samples  (n=28)  were inoculated  in  Middlebrook 7H9 broth. 
AFB   Smear – culture correlation   
                             Table – 16.      Correlation of   AFB  smear and Culture   in 
ADA elevated samples (n=28) 
AFB Smear Culture positive  Culture negative 
Smear positive 9 1 
Smear negative 1 17 
 
                    Sensitivity = 90%, Specificity= 94.44% 
                       Table -17.    ADA Vs   Culture Positivity (n=28) 
ADA Culture + Culture - 
ADA > 40 10 18 
ADA< 40 NA (not inoculated) not 
applicable 
NA 
 
MPT 64 Ag test: 
                 All culture positive samples (n=10)  were  positive for MPT 64 Ag 
detection test. 
                 Total   culture positive        -   10, MPT 64 Ag  Test  positive   -   1 
  
 
 
 
 
 
 
 
 
DISCUSSION 
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                                                    DISCUSSION 
                 Pleural infection remains a major healthcare problem. The incidence of 
pleural effusion and mortality   is rising in adults as well as children. Because of the 
changing trends in bacteriology of empyema, Clinicians need to know the local 
prevalence of micro organisms in empyema (and their antibiotics susceptibility) to 
guide antimicrobial therapy. Shifts in bacteriology can be lead to variations in 
clinical presentation, antibiotic response and outcome. The   study is focused on the   
knowledge of likely prevalent pathogens and  their antimicrobial   resistance pattern  
which would help the  physician  in the framing of antibiotic policy and better   
management  of patients. 
                           
               The possibility of tuberculous pleural effusion should be considered in 
every patient with an undiagnosed pleural effusion, for if this diagnosis is not made 
the patient  will recover only to have a high likelihood of subsequently   developing 
pulmonary or extrapulmonary  tuberculosis. Between 3% and 25% of patients with   
tuberculosis will have tuberculous pleuritis.(25) Early diagnosis and treatment will 
reduce the mortality. 
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                In the present study 150 patients   with pleural effusion were included.     
Mainly they were classified into 4 categories. 1. Tuberculous effusion, 2.Malignant 
pleural effusion, 3. Parapneumonic effusion, 4.Others. 
                Statistical   analysis was done using SPSS 21 software. The   predominant 
age   group  affected  were from 18 yrs to 30 yrs (41) Percentage was 27.33%           
p value = 0.016.( Significant )  But in patient with Malignant effusion  the  most  
common age group was  > 60 yrs.   In a previous study by Dhital et al(20) also 
showed this  finding  that is most common age group as  21- 30 yrs. 
                 Males were affected more than females   65.33%. p value =  0.016. From 
the observation,   in the Study   Right sided pleural effusion was more common   
than Left side. Right sided effusion was 56.66%   where   as   percentage of left 
sided effusion was 39.33%.  p value =0.00 (significant).  
                Para   pneumonic pleural effusion was   the most common etiology in the 
study contributing to 24%. The next common associated condition was Malignancy 
which was 16%. Tuberculosis was observed   to cause pleural effusion as third most 
common etiology   in the study which was 9.33%. Other than these causes all other 
Pleural effusion were involved in Fourth category. This group includes   patients 
with Congestive cardiac failure, Chronic kidney disease, Rhe umatic heart disease, 
Systemic lupus erythematosus, Rheumatoid factor, Polyserositis  and  Postoperative 
patients. The retrospective study done by Dhital et al showed   Tubercular effusion   
was most common followed by parapneumonic effusion.(20) 
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                Bacterial culture positivity occurred in exudative pleural effusion more 
than transudate. Patients with Para pneumonic effusion showed culture positivity 
than other 3 groups. (P value = 0.000. Significant)  Klebsiella pneumoniae was the 
predominant isolate in the Parapneumonic group. 
 
                Among 150 patients, 106 showed culture negative. 44 samples had 
bacterial growth. In this study the percentage of culture negative was 70.66%. 
Percentage of positive cultures was 29.33%.  In a retrospective study conducted at 
one of Asia’s largest chest and Tuberculosis hospital by Jain Sonali the percentage 
Positive culture was 17.7%.(9) 
                 There was a wide variation of Microbiological diagnosis in the earlier 
studies. A lower positive culture rates of Pleural fluid cultures  has also been 
observed in  Indian studies like  that of Mohanty et al (21) (15.3%)and in western 
studies by Barnes et al ( 1.4%)(21) and Walshe et al (3.5%).(21) 
                      The reason for the variations in positivity rates of  pleural  fluids  were 
attributed to differences in  diagnostic techniques, antibiotic usage  and  the 
prevalence of effusions caused by infective process. These variations also may be 
due to differences in study population.(21) If the Microbiological  studies have been  
done only on exudative   pleural effusion, it  could  definitely enhance  the yield of  
fluid cultures. This is not practically possible because we cannot delay culture till 
the biochemical results are obtained. Second cause of low yield may be the empiric 
administration of antibiotics to the patients before thoracocentesis. 
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                 In this study   Gram negative bacilli occurred predominantly. Percentage 
of GNB isolates was 68.18% (n=30). Staphylococcus aureus was the predominant 
pathogen isolated in 31.8 % (n= 14). 2 isolate were MRSA (14.28%).  Among GNB   
Klebsiella pneumoniae was the predominant isolate. Klebsiella pneumoniae  was 
isolated  from 13 samples (29.54%). Among 13 isolate 4 were ESBL producers. 
Klebsiella oxytoca was isolated   in two patients (4.54%). Pseudomonas aeruginosa 
was isolated from 6 samples (13.63%). Acinetobacter baumanni was isolated from 
6 patients (13.63%). Escherichia coli are isolated from 3 patients with pleural 
effusion (6.82%). 
                 In the earlier study by Mohanty et al percentage of GNB was 86.4% and 
Gram positive cocci was 13.6%. But that study was conducted for 4 yrs Jan 2001 – 
Dec 2004. 2906 Pleural fluid samples were taken. Sample size was large. So taking 
these points our present study correlate with this study by Mohanty et al.(21)  In that 
study most frequent GNB was Acinetobacter spp  (27.7 %).In an another study   
also, conducted by Jain sonali RBIPMT, Delhi(9), isolation  of GNB was in higher 
rates  88.4%. Klebsiella pneumoniae was most common in the study of Thiago 
Lisboa.(10) In the present study also showed K.pneumoniae as a predominant  
pathogen. 
                 ESBL production was highest in E.coli  and K.oxytoca( 100%), Followed 
by K.pneumoniae  (30.76% ). This type of observation was also seen in the study by 
Jan sonali.(9) 
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                          MRSA in the present study was 14.28%, but  in the earlier study by Jain 
sonali  was 79.3%.  The prevalence of MRSA from different part of the country 
varies from 30- 85%.(9) In this study the prevalence of MRSA is low. 
 
                  Pleural space  infections were caused by more than one micro organisms 
or  polymcrobial  in earlier   studies  like that of  Study by  Jain sonali(9),  Nick A. 
Maskell.(12) Mostly due to combination of P.aeruginosa and   a  Enterobacteriaceae  
group organism.  Mixed aerobic and anaerobic infections were also reported in 
these studies. (10, 11) But in the present study only single organism was isolated in all 
the culture positive cases. 
                 In some earlier studies like that of  Thiago (10), J porcel (11)  and   The First 
Multicentre  Intrapleural Sepsis trial a cohort study of Nick A Maskel et al (12) 
showed  Streptococcus species “ intermedius – anginosus – constellatus  ” group 
and Streptococcus Pneumoniae as the predominant pathogens. Anaerobic infections 
like   Bacteriodes, Fusobacterium , Provetella    were isolated in earlier studies of  J 
porcel (11)  and The First Multicentre  Intrapleural sepsis trial a cohort study of Nick 
A Maskel et al.(12) But in the present study Streptococcus species  and Streptococcus 
Pneumoniae  were not isolated. Anaerobic culture also not done in the present 
study. So anaerobes also not isolated. 
                 Isolation of anaerobes and fungi was not included in the study. 
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                 Second part of the study was estimation of Adenosine Deaminase level 
and Correlation of elevated ADA levels with the diagnosis of Tuberculous effusion 
by Liquid culture method. Middlebrook 7H9 broth media was used for the 
culture.(16) 
                Among 150 samples ADA values were elevated mostly in   Tuberculous 
pleural effusion. Group I had   14 patients   with the   diagnosis TB pleural effusion.    
All 14 had elevated ADA level. Among these patients 10 patients showed AFB 
smear positive.  Among these 10 cultures was positive in 9 samples. Among Pleural 
fluid AFB smear negative   4 samples, Mycobacterial culture was positive in one 
sample. This patient showed smear positive in Sputum sample.  Another one patient  
among  these 4 Pleural fluid AFB smear negative patients showed AFB smear 
positivity in bronchial wash but pleural fluid culture showed negative result. This is 
may be due to the presence of very less bacillary load.  ii. Patient was on ATT for 2 
months. 
                 Mean ADA value for the TB pleural effusion group was - 80.45 U/l  
 
 Diagnostic category Mean ADA value U/l 
1 TB pleural effusion (GroupI) 80.45 
2 Malignant pleural effusion( Group II) 28.085 
3 Para pneumonic effusion (G-III) 20.18 
4 Others (CCF, CKD, RHD, SLE..etc) 
(Group  IV) 
18.441 
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    Group 2 was malignant pleural effusion.  Totally 27 patient had malignant 
pleural effusion among 150 patients. Among these 14 (51.85%) samples showed 
increased ADA level. All were culture negative in Middlebrook7H9 broth. Mean 
ADA level was 28.085 U/l.  
                Group 3 and Group 4 had normal ADA levels. On comparison of mean 
ADA among the four groups using post hoc tests, the p values are significant. 
Negative predictive value was higher.  From this it denotes ADA   level elevation 
correlate Tubercular etiology in TB prevalent area like that of ours. Normal ADA 
levels also have significance in ruling out TB as an etiology of Pleural effusion. 
                  MPT64 Ag detection was done for all culture positive samples for 
confirmation and identification of Mycobacterium spp.(10) All are positive. So 
positive for Mycobacterial tuberculosis complex. Other tests for identification of 
Mycobacterial species like Niacin test, Catalase test,  Growth in Para nitro benzoic 
acid were not done because these tests require  colonies  from  solid culture like LJ 
media 
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SUMMARY 
• In this study 150  patients with pleural effusion  those who are admitted in 
the Institute of Internal Medicine   and   Institute of Thoracic Medicine were 
included. Majority of the patients were in the age group of 18 -30 yrs, with 
male preponderance. 
• Right sided Pleural effusion was more common than left sided effusion and 
bilateral effusion (50.66%). 
• Exudative pleural effusion showed more culture positivity than transudates. 
Culture was positive most commonly in patients with Parapneumonic 
effusion71.42%. Percentage of total positive cultures was 29.54%. 
• Gram negative bacilli were most commonly isolated organism Percentage 
was 68.18%. Among Gram negative bacilli  Klebsiella pneumoniae was the 
predominant one 43.33%. 
• Staphylococcus aureus was the only Gram positive cocci isolated. 
Percentage was 31.81%. 
• ESBL production occurred mostly in Escherichia coli and Klebsiella 
oxytoca (100%). In Klebsiella pneumoniae ESBL production was 30.76%. 
• Acinetobacter baumanni   was isolated from 6 samples (13.63%). 
Pseudomonas aeruginosa was isolated   from 6 samples (13.63%). 
• Among  Staphylococcus aureus  MRSA were 14.28%.  
 
 
75 
 
• Adenosine de aminase levels were elevated in 28 samples (18.66%). 
• Among ADA elevated samples (Total 28) 14 patients had the diagnosis of   
TB, 14 had Malignancy. Total number of malignant pleural effusion was 27 
among 150.ie In TB pleural effusion ADA levels were elevated in 100%. 
• In malignancy ADA levels elevated in 51.85%. 
• Mean ADA value in TB pleural effusion was 80.45 U/l. 
• Mean ADA value in Malignancy was 28.085%. 
• Comparison of ADA values  among  TB Pleural effusion , Malignant 
pleural effusion, Parapneumonic effusion   and other effusions by post hoc 
tests there was  a significance (pvalue =0.000) for TB pleural effusion. 
• Negative predictive value of ADA for TB was higher in the study. ie Lower 
ADA values  rules out Tubercular etiology. 
• AFB positive samples were 10. Among these 9 showed Culture positive 
(90%).Among AFB negative ADA elevated 18 samples one sample showed 
Culture positive. Sensitivity -90%, Specificity- 94.44%. 
• All culture positive samples (10) were also positive for MPT64 Ag test. 
(100%) 
                                              
                                            
 
 
 
CONCLUSION
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                                               CONCLUSION 
•  Bacteriology of Pleural effusion has changing trends. Physicians need to 
know the local prevalence of Microorganism and their antibiotic 
susceptibility pattern.  
• In Pleural effusion of unknown etiology after repeated investigation ADA 
estimation can be used as initial screening test for ruling out Tubercular 
etiology.  
• ADA   estimation can be done for diagnosis for Tuberculous pleural effusion 
in developing countries like India where TB is a prevalent condition with 
high mortality. 
• ADA   estimation is cost effective and can detect TB effusion earlier 
than Pleural biopsy tissue histology, pleural biopsy tissue culture  and 
Pleural fluid  culture.                        
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FIG 1:PHENOTYPIC CONFIRMATION DISC DIFFUSION TEST (PCDDT) 
FOR ESBL PRODUCTION 
 
FIG 2. E - TEST FOR DETECTION OF MIC OF VANCOMYCIN  
 
FIG 3,4,5,6 ADA ESTIMATON 
     
 
 
 
   
 
FIG 7 PLEURAL FLUID AFB SMEAR POSITIVE 
 
FIG 8 MPT 64 Ag POSITVE 
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APPENDIX – I 
 
ABBREVATIONS 
ADA    -   Adenosine deaminase  
GPC     -   Gram positive cocci 
GNB    -   Gram negative bacilli 
AFB     -    Acid fast bacilli  
AK       -    Amikacin 
GM      -    Gentamicin 
CIP      -     Ciprofloxacin 
CTX    -     Cefotaxime 
CAZ    -     Ceftazdime 
CAC    -     CAZ+ clavunulate 
PEN     -     Penicillin 
AMP    -     Amoxicillin 
ERY     -     Erythromycin 
COT    -      Cotrimoxazole  
 VAN   -     Vancomycin  
 CK      -     Chloramphenicol  
 TET    -      Teracycline  
 IMI     -       Imipenam  
 PT       -      Piperacillin-Tazobactum 
 CLSI   -      Clinical & Laboratory Standards Institute  
 
ATCC  -      American Type Culture Collections  
 
MIC     -       Minimum Inhibitory Concentration  
 
 
MRSA -       Methicillin Resistant Staphylococcus aureus  
CCF     -   Congestive cardiac failure 
TB       -    Tuberculosis 
CRF     -    Chronic renal failure 
RA       -    Rheumatoid arthritis 
SLE      -    Systemic lupus erythematosis 
PPE      -    Parapneumonic effusion 
CA       -    Carcinoma  
MOTT  -    Mycobacterium other than tuberculosis 
NTM    -     Non tuberculosis mycobacterium   
F          -     Female 
M         -     Male                                 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX- II 
 
PREPARATION OF MIDDLEBROOK 7H9 BROTH 
  
 
 
                 Himedia  Middlebrook 7H9 broth   base powder was used to prepare 
Liquid  media. 
Preparation: 
                 Weighed   2.35g of dehydrated base (M 198)into a 500ml litre flask, 
added 450ml  distilled water  and mixed well. Autoclaved for 20 mins at 120̊̊c.  
Added   2ml  Glycerol after the broth temperature has come down.  Added OADC 
supplement (Himedia FD 019) finally. Mixed well, distributed in 10- 15 ml amounts 
in   sterile bottles. Bottles were sealed using cap sealer. 
 
ADC supplement 
• Bovine albumin, Fraction V: 1g 
• Glucose, A. R. (dextrose): 4g. 
• Catalase: 3 mg  
• Oleic acid 
 
 
 
 
 
 
 
 
 
APPENDIX – III 
KIT INSERTS 
  
 
 KIT INSERTS 
KIT INSERTS 
 
 
KIT INSERTS 
 
 
 
 
  
 
ANNEXURE 
ANNEXEURE I 
ETHICAL CLEARANCE 
 
ANNEXURE - II      PROFORMA 
 
Name: 
 
Age:                                           IP NO: 
 
Sex:                   Ward NO: 
 
Occupation: 
 
Address: 
 
 
Presenting complaints: 
 
 
Personal history: 
 
 
Past history: 
                      H/O exposure to tuberculosis 
 
Family history: 
 
 
Microbiological investigation: 
 
Direct Examination: 
              Gram staining:  
                               
              AFB staining: 
 
Culture:                                                                          Isolate identified: 
 
            MAC: 
            BAP: 
            CAP: 
  
Adenosine deaminase level:                                         Antimicrobial Sensitivity: 
 
 
Middlebrook 7H9 Broth: 
 
 
Rapid test for MPT 64 Ag: 
ANNEXURE-III 
CONSENT FORM 
STUDY TITLE: “A Study on Bacteriological profile of Pleural effusion and   
study on   Adenosine deaminase level in the diagnosis of Tuberculous and Non 
Tuberculous Pleural effusion ”. 
I…………………………………………, hereby give consent to participate in the 
study conducted by Dr.M.MALA, Post graduate at Institute of Microbiology, 
Madras Medical College, Chennai and to use my personal clinical data and the 
result of investigations for the purpose of analysis and to study the nature of the 
disease, I also give consent to give my sample for further investigations. I also learn 
that there is no additional risk in this study. I also give my consent for my 
investigator to publish the data in any forum or journal 
 
Signature/ Thumb impression of the patient/ relative                        Place: 
 
 
 
Patient Name & Address:                                                                  Date: 
 
 
 
 
 
Signature of the investigator                       Signature of the guide:  
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